2019年 6月 18日
Brazilian medical device market regulator ANVISA recently discussed revisions to planned requirements for custom-made devices with Emergo by UL consultants prior to finalization and official publication of the new rules.
Subjects discussed in the meeting between ANVISA and Emergo by UL included evidence that Brazilian regulators are seeing a major increase in submissions for custom-made devices including 3D-printed medical products in recent years, prompting the need to define specific criteria for these devices including their importation and manufacturing.
Under ANVISA’s current system, custom- and patient-specific device applications must go through a specialized submission process for ANVISA review, with no specific Brazilian regulations to serve as reference in these cases. Thus, with a lot of back and forth between ANVISA, applicants and market sources without the support of regulatory guidelines, market access for custom-made devices can take a lot of time.
ANVISA’s proposed new regulatory system for custom-made devices distinguishes between three main types of such products:
This new regulation will define specific criteria based on the device risk classification for the notification of custom-made manufacturing, importation and vigilance responsibilities, as well as detail a clearer Brazilian market pathway for patient-specific and adaptable medical devices.
Luiz Levy, Director of QA/RA at Emergo by UL in São Paulo who attended the meeting with ANVISA, observed, “ANVISA made many interesting updates after receiving comments from the market, and these updates should allow companies to properly document custom-made device manufacturing and importing requests.
“Additionally, ANVISA updated its regulation of devices classified as patient-specific, which as a consequence will certainly help devices with these features reach end-users and patients faster in Brazil.”